Christopher K. Cullum

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study.

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study.

Journal: The journal of headache and pain

Published: February 18, 2025

Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study.

Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study.

Journal: Scientific reports

Published: March 05, 2024

No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.

No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.

Journal: Cephalalgia : an international journal of headache

Published: January 12, 2024

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study.

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study.

Journal: Frontiers in neurology

Published: May 21, 2023

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.

Journal: The journal of headache and pain

Published: April 25, 2023

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.

Journal: The journal of headache and pain

Published: May 06, 2022

Use of Non-pharmacological Therapies in Individuals With Migraine Eligible for Treatment With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)-Signaling: A Single-Center Cross-Sectional Observational Study.

Use of Non-pharmacological Therapies in Individuals With Migraine Eligible for Treatment With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)-Signaling: A Single-Center Cross-Sectional Observational Study.

Journal: Frontiers in pain research (Lausanne, Switzerland)

Published: May 03, 2022

Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report.

Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report.

Journal: BMC neurology

Published: April 21, 2021

Neuromuscular Electrical Stimulation Preserves Leg Lean Mass in Geriatric Patients.

Neuromuscular Electrical Stimulation Preserves Leg Lean Mass in Geriatric Patients.

Journal: Medicine and science in sports and exercise

Published: November 06, 2019

Inflammation Relates to Resistance Training-induced Hypertrophy in Elderly Patients.

Inflammation Relates to Resistance Training-induced Hypertrophy in Elderly Patients.

Journal: Medicine and science in sports and exercise

Published: January 28, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026